“Buffalo hump” in men with HIV-1 infection

BACKGROUND Enlargement of the dorsocervical fat pad ("buffalo hump") has been reported in numerous HIV-1-infected patients. Some investigators have speculated that this finding is associated with protease-inhibitor treatment. METHODS Between June, 1995, and October, 1997, we studied eight HIV-1-infected men who had developed a buffalo hump while otherwise stable on antiretroviral therapy. Measurement of 24 h urinary free cortisol excretion and an overnight low-dose dexamethasone suppression test were done to screen for Cushing's syndrome. In one patient, plasma cortisol concentrations were measured every 4 h for 24 h to assess the circadian rhythm of cortisol. Results of total and regional body-composition analysis by dual-energy X-ray absorptiometry, and glucose, cholesterol, triglyceride, and cortisol concentrations were compared with those obtained in a control population of 15 HIV-1-positive men whose age, body-mass index (BMI), and CD4-lymphocyte count were within the range of values in the eight study patients. FINDINGS The eight patients with a buffalo hump were clinically stable on various antiretroviral regimens, four of which included a protease inhibitor. No other signs of Cushing's syndrome were observed, and plasma cortisol values did not differ significantly from those of controls. 24 h urinary free cortisol excretion was normal in seven patients and slightly raised in one (248 nmoles). In this patient, a repeat 24 h urinary free cortisol was 175 nmoles and plasma cortisol concentrations over 24 h showed a normal circadian pattern (nadir 83 nmol/L at 2400 h). All eight patients had normal suppression of cortisol values after dexamethasone 1 mg (plasma cortisol less than 83 nmol/L). When compared with HIV-1-positive controls, men with a buffalo hump had a significantly greater proportion of fat in the trunk region, suggesting central fat accumulation. Triglyceride but not cholesterol values were higher in the patients than in controls but this difference was not significant. Fasting glucose values did not differ significantly. INTERPRETATION The development of a buffalo hump cannot be attributed to hypercortisolism in these eight men. Furthermore, its occurrence is not unique to patients on protease inhibitors. Although the mechanism for dorsocervical fat accumulation is unclear, we speculate that regional abnormalities in lipogenesis and lipolysis occur, possibly influenced by the hormonal and metabolic changes seen with HIV-1 infection and its treatment.

[1]  M. Schambelan,et al.  Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[2]  P. Björntorp,et al.  Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. , 1988, The Journal of clinical endocrinology and metabolism.

[3]  Y. Matsuzawa,et al.  Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. , 1987, Metabolism: clinical and experimental.

[4]  J. Yanovski,et al.  Glucocorticoid action and the clinical features of Cushing's syndrome. , 1994, Endocrinology and metabolism clinics of North America.

[5]  B. Murphy,et al.  Some studies of the protein-binding of steroids and their application to the routine micro and ultramicro measurement of various steroids in body fluids by competitive protein-binding radioassay. , 1967, The Journal of clinical endocrinology and metabolism.

[6]  P. Volberding,et al.  The Medical Management of AIDS , 1988 .

[7]  L. Crapo Cushing's syndrome: a review of diagnostic tests. , 1979, Metabolism: clinical and experimental.

[8]  P. Forsham,et al.  A RAPID SCREENING TEST FOR CUSHING'S SYNDROME. , 1965, JAMA.

[9]  R B Mazess,et al.  Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. , 1990, The American journal of clinical nutrition.

[10]  W. Winkelmann,et al.  DIAGNOSIS OF CUSHING'S SYNDROME , 1969 .

[11]  Y. Matsuzawa,et al.  Pathophysiology and Pathogenesis of Visceral Fat Obesity , 1993, Annals of the New York Academy of Sciences.

[12]  J. Lennox,et al.  Benign symmetric lipomatosis associated with protease inhibitors , 1997, The Lancet.

[13]  K. Feingold,et al.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. , 1992, The Journal of clinical endocrinology and metabolism.

[14]  P. Björntorp The regulation of adipose tissue distribution in humans. , 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[15]  C. Grunfeld,et al.  Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. , 1993, The Journal of clinical endocrinology and metabolism.

[16]  C. Sum,et al.  Overnight (1 mg) dexamethasone suppression testing reliably distinguishes non-cushingoid obesity from Cushing's syndrome , 1991, Steroids.

[17]  G. Chrousos,et al.  Hypercortisolism and Obesity , 1995, Annals of the New York Academy of Sciences.

[18]  F. H. Tyler,et al.  DIAGNOSIS OF CUSHING'S SYNDROME; SINGLE DOSE DEXAMETHASONE SUPPRESSION TEST. , 1965, Archives of internal medicine.

[19]  P. Björntorp,et al.  Steroid hormone receptors in human adipose tissues. , 1990, The Journal of clinical endocrinology and metabolism.

[20]  P. Stewart,et al.  Does central obesity reflect “Cushing's disease of the omentum”? , 1997, The Lancet.

[21]  藤岡 滋典 Contribution of intraabdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity , 1987 .

[22]  J. Doppman,et al.  Biochemical and radiologic diagnosis of Cushing's syndrome. , 1994, Endocrinology and metabolism clinics of North America.